In 2000, the predecessor of Keanrui Group-Beijing Tradestar Pharmaceutical Technology Development Co., Ltd. was found.
In 2024, Yunnan Yong'an Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Keanrui Pharmaceutical Group, has achieved another milestone in the field of pharmaceutical innovation by being awarded the titles of "Specialized, Refined, Characterized and Innovative Small and Medium-sized Enterprise" and "Innovative Small and Medium-sized Enterprise" issued by the Department of Industry and Information Technology of Yunnan Provincial. This official certification not only highlights Yunnan Yong'an's profound expertise and continuous innovation capabilities in its field, but also injects new vitality into the development of the company and even the local pharmaceutical industry.
In 2006, the classic product of the nervous system - Bosijie? - Monosialotetrahexosylganglioside Sodium injection was launched, achieving a good market effect, and consistently maintaining a runner-up position in terms.
In 2007, a strategic cooperation with Tianjin Pharmaceutical Group was established, and the marketing of Cephalexin Dispersible Tablets - Xifuni? and Cephalexin Capsules - Shifuni? was planned. In just three years, by 2011, the market share of Xifuni reached the first place, and Shifuni? reached the fourth place. Xifuni has long occupied the first place in the category of oral cephalosporin antibiotics in Chinese public medical institutions, with an annual sales scale of over one billion yuan.
In 2013, the acquisition of Beijing Jinyang Likang Pharmaceutical Co., Ltd. (now Beijing Keanrui Pharmaceutical Operation Co., Ltd.) was completed.
In 2014，Yunnan Yong`an Pharmaceutical Co., Ltd. Was acquired.
In 2014, the Ganfuneng? - Ademetionine Butanedisulfonate for Injection, developed in cooperation with Zhejiang Zhenyuan Pharmaceutical Co., Ltd., was approved for marketing and quickly emerged as one of the leading products in Chinese liver disease treatment market.
In 2016, Tibet Jian Lian Pharmaceutical Co., Ltd. (now Meirui (Tibet) Pharmaceutical Co., Ltd.) and Nanjing Meirui Pharmaceutical Co., Ltd. were acquired.
In 2019, the groundbreaking ceremony of Beijing Keanrui Health Science and Technology Innovation Industrial Park project was grandly held in Fangshan, which is a key planning project of Fangshan District, Beijing. The project covers an area of 50,000 square meters, providing one-stop nanny service for entrepreneurs with dreams and helping the establishment and development of small and micro enterprises.
In 2023, Keanrui (Beijing) Pharmaceutical Group Co., Ltd. was separated from Trade Star Group and became a group company focused on the pharmaceutical industry. Trade Star Technology Industry Group focuses on investment in the health industry, construction of industrial parks, and incubation of innovative projects. While Trade Star Technology Industry Group is building the Beijing Industrial Park, the Nanjing Health Industrial Park is also in planning and preparation.
In 2024, Yunnan Yong'an Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Keanrui Pharmaceutical Group, has achieved another milestone in the field of pharmaceutical innovation by being awarded the titles of "Specialized, Refined, Characterized and Innovative Small and Medium-sized Enterprise" and "Innovative Small and Medium-sized Enterprise" issued by the Department of Industry and Information Technology of Yunnan Provincial. This official certification not only highlights Yunnan Yong'an's profound expertise and continuous innovation capabilities in its field, but also injects new vitality into the development of the company and even the local pharmaceutical industry.